Announcements Trials
Browse Landscape

Status

No longer available 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 20Observational 2Expanded_access 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 1CNS 1

Conditions

Glioma 1Gastrointestinal Stromal Tumors 1GIST 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × avapritinib × Clear all
NCT04714086 2024-10-24

Expanded Access Program for Avapritinib

Blueprint Medicines Corporation

No longer available
CNSGastrointestinalSarcoma

Glioma, Gastrointestinal Stromal Tumors

NCT03862885 2020-07-27

Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

Blueprint Medicines Corporation

Approved for marketing
Sarcoma

GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡